Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 13, 2020 in Diabetes mellitus | 0 comments

In a nutshell

This study compared the safety of two medications, linagliptin (Trajenta) and glimepiride (Amaryl). It found that the medications had the same risk of heart attack, stroke, or heart-related death, while linagliptin was associated with a lower risk of hypoglycemia (dangerously low blood glucose level).

Some background

There are many different treatments available for type 2 diabetes (T2D). Safety is very important when choosing a medication, especially for older patients. Some diabetic medications can be associated with a risk of heart problems, weight gain, or hypoglycemia. It is not fully clear which medications are the safest.

Methods & findings

This study involved 6,033 patients with poorly controlled T2D. Group 1 was treated with linagliptin while group 2 was treated with glimepiride. Participants were followed for an average of 6.3 years.

The two groups had the same risk of stroke, heart attack, or heart disease-related death. The two groups also showed similar improvements in blood glucose control. However, the risk of moderate-to-severe hypoglycemia was 82% lower in the linagliptin group. This risk was similar across all age groups. 

Patients on linagliptin also had an average weight 1.54 kg lower than the glimepiride group. The linagliptin group also experienced fewer falls and broken bones.

The bottom line

This study showed that linagliptin may cause less hypoglycemia, falls, and broken bones than glimepiride.  The authors suggest that this may be a safer choice for older patients who are at higher risk from these complications.

The fine print

Some information about the frailty of older participants was not included in this study. More studies are needed to confirm that these findings apply to the average elderly diabetic person. This trial was funded by Boehringer Ingelheim, the manufacturer of linagliptin.

Published By :

Diabetes, Obesity and Metabolism

Date :

Nov 12, 2020

Original Title :

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial.

click here to get personalized updates